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Charcot-Marie-Tooth disease (CMT) is the most common 
neuromuscular disorder. The autosomal dominant and de-
myelinating type (CMT1) associated with duplication of the 
PMP22 gene (CMT1A) is the most prevalent subtype around 
the world, including Brazil1, and is typically associated with 
mild or moderate neuropathy. Point mutations in the same 
gene (CMT1E) are extremely rare2 and typically result in se-
vere demyelinating neuropathies, including Dejerine-Sottas 
syndrome and congenital hypomyelinating neuropathy3. 
Interestingly, CMT1 patients harboring the same mutation 
may develop different manifestations, even in identical twins. 
Herein, we present Brazilian siblings harboring a previ-
ously described point mutation in the PMP22 gene that man-
ifested as an unexpected clinical phenotype.
CASE REPORT
Both patients, one female and one male, were observed 
at the Neuromuscular Outpatient Clinics, UNIFESP, at the 
ages of 29 and 38 years old, respectively. Their family history 
indicated that the father had similar manifestations. They re-
ported normal development up to the age of 12 and 11 years 
old, respectively, at which point they developed dropped feet 
and began to trip and fall. Thereafter, their disease slowly pro-
gressed. A physical examination identified severe distal weak-
ness and atrophy in both the lower and upper limbs. The pain, 
tactile and vibration senses were severely decreased distally, 
and tendon jerks were absent. The peripheral nerves were hy-
pertrophic, and both patients had pes cavus. The sister had 
claw hands, while the brother had a hand tremor. Interestingly, 
both patients had bilateral proptosis with preserved ocular 
movements. No malformation, including craniostenosis, was 
detected. Nerve conduction studies were performed, and no 
sensory or motor potential was recorded in the limbs; the 
blink reflex demonstrated R1 and R2 responses with very 
prolonged latencies. After obtaining informed consent, DNA 
analyses demonstrated that the PMP22 duplication was ab-
sent, but a point mutation was detected in both patients at 
position c.T47C, resulting in p16 Leuc-to-Prol in the protein.
DISCUSSION
The mutation found in these patients has been reported 
previously in a family with a disabling phenotype (Dejerine-
Sottas), including severe distal weakness, marked proximal 
paresis, severe kyphoscoliosis and foot and hand deformities4. 
The nerve conduction velocities were extremely low, and pa-
thology was more severe than typically observed for CMT1A. 
The siblings described in our report had a typical CMT1 
phenotype. Additionally, both had bilateral proptosis whose 
investigation for the known causes5 resulted negative, raising 
the possibility that it is related to the harbored mutation. 
Familiar bilateral proptosis is an extremely uncommon 
condition that typically appears in patients with hypertir-
eoidism or cranial malformations. Rare reports of patients 
with proptosis associated with peripheral neuropathy have 
been described in the literature. However, they are typi-
cally part of a more complex neurological picture, such 
as that observed in mitochondrial disorders (e.g., due to 
OPA1 mutations) or genetic dysmorphic syndromes (e.g., 
Cardiofaciocutaneous syndrome).
To the best of our knowledge, proptosis has not been de-
scribed in CMT1A or CMT1E, but variability in the CMT1 
phenotype is a well-known phenomenon, even in identical 
twins. Unfortunately, the remaining members of this family 
were not available for examination. The function of PMP22 
is still extremely unclear. Apparently, there is no significant 
function related to the eyes or orbita. If the proptosis ob-
served in these patients is truly related to the detected muta-
tion, PMP22 must have an unknown function.
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